ID   HCT-116-MEK-R
AC   CVCL_V401
DR   cancercelllines; CVCL_V401
DR   Cosmic; 1927247
DR   Wikidata; Q54882015
RX   PubMed=22402123;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Leu450Ter (c.1349delT) (p.Leu450fs) (c.1344delT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0291 ! HCT 116
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 16-04-14; Last updated: 05-10-23; Version: 15
//
RX   PubMed=22402123; DOI=10.1158/1535-7163.MCT-11-1010;
RA   Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P.,
RA   Haverty P.M., Soriano R., Forrest W.F., Heldens S., Chen H.-F., Toy K.,
RA   Ha C., Zhou W., Song K., Friedman L.S., Amler L.C., Hampton G.M.,
RA   Moffat J., Belvin M.P., Lackner M.R.;
RT   "ERK inhibition overcomes acquired resistance to MEK inhibitors.";
RL   Mol. Cancer Ther. 11:1143-1154(2012).
//